🔎 Trials Near Me

Hjem › Akut myeloid leukæmi › Illinois › Chicago

Akut myeloid leukæmi kliniske forsøg i Chicago, IL

26 studier for Akut myeloid leukæmi søger deltagere på steder i og omkring Chicago (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
  • Mount Sinai Hospital Medical Center, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • og 1 flere
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

RekruttererFase 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Alder 18 til 59 · Alle køn · Opdateret 28. sep. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • University of Chicago Medicine, Chicago
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • og 1 flere
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Alder 18 til 59 · Alle køn · Opdateret 22. sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
6 Months – 21 Years · Alle køn · Opdateret 17. sep. 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

RekruttererFase 1/2
  • The University of Chicago Medical Center, Chicago
30 Days · Alle køn · Opdateret 16. sep. 2026 · NCT04065399

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

RekruttererFase 1/2
  • University of Chicago, Chicago
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

RekruttererFase 3
  • Lurie Children's Hospital-Chicago, Chicago
Alder 1 til 25 · Alle køn · Opdateret 4. sep. 2026 · NCT07022678

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • US-Chigago IL-UHCHICAGO, Chicago
Alder 18 og opefter · Alle køn · Opdateret 1. sep. 2026 · NCT07223814

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

RekruttererFase 1/2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
  • Comer Children's Hospital, Chicago
29 Days – 21 Years · Alle køn · Opdateret 24. aug. 2026 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RekruttererFase 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekruttererObservationsstudie
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • og 2 flere
Alle aldre · Alle køn · Opdateret 6. jul. 2026 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

RekruttererFase 1
  • University of Chicago, Chicago
Alder 13 og opefter · Alle køn · Opdateret 5. maj 2026 · NCT04771572

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

RekruttererFase 1/2
  • Northwestern University, Chicago
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2026 · NCT05732103

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

RekruttererFase 1/2
  • Northwestern, Chicago
Alder 12 og opefter · Alle køn · Opdateret 24. mar. 2026 · NCT04988555

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

RekruttererFase 1
  • Northwestern Medicine, Chicago
Alder 12 og opefter · Alle køn · Opdateret 16. mar. 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RekruttererFase 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

RekruttererFase 1
  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2025 · NCT06501196

Akut myeloid leukæmi forsøg i andre byer

Andre studier i Chicago

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.